Clopidogrel

CLINICAL USE

Antiplatelet agent

DOSE IN NORMAL RENAL FUNCTION

75 mg dailyAcute coronary syndrome and post-MI: 300 mg loading dose then 75 mg daily (with aspirin 75–325 mg daily)

PHARMACOKINETICS

Molecular weight :419.9 (as hydrogen sulphate)

%Protein binding :98

%Excreted unchanged in urine : 50

Volume of distribution (L/kg) :No data

half-life – normal/ESRD (hrs) :8 (active metabolite)/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAnticoagulants: enhanced anticoagulant effect with coumarins and phenindione; manufacturer advises to avoid concomitant use with warfarinHeparin: increased risk of bleeding

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home